Private Equity Purchases RPS, Plans to Merge With PRA

By Zachary Brennan contact

- Last updated on GMT

Private Equity Purchases RPS, Plans to Merge With PRA

Related tags: Contract research organization, Investment

Private equity firm KKR announced today it will acquire RPS (ReSearch Pharmaceutical Services) from Warburg Pincus and will merge the company with PRA International. 

After the merger of the two CROs (contract research organizations), PRA CEO Colin Shannon is expected to lead the combined company, though RPS will operate as a division of PRA under the leadership of RPS President Harris Koffer and EVP Samir Shah.

"This transaction represents the next step in the evolution of RPS and its Embedded service model​,” Koffer said.

KKR purchased PRA late last month for about $1.3B​ after the CRO announced plans to go public.

Shannon added in a statement, "By bringing together PRA and RPS, we will be able to offer a more comprehensive range of services across all segments of the biopharmaceutical industry through our expanded capabilities, therapeutic expertise, and greater geographic presence​."

He also told us last month that KKR will not interfere in the company’s operations.

The transaction is expected to close in Q3 of 2013 and is subject to regulatory approvals and other closing conditions.

Citigroup acted as exclusive financial advisor and Kirkland & Ellis LLP acted as legal advisor to RPS. Credit Suisse, Jefferies LLC, and UBS Investment Bankserved as financial advisors to KKR. 

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us


View more